FDA Approval Summary: Lutetium Lu 177 Vipivotide Tetraxetan for Patients with Metastatic Castration-Resistant Prostate Cancer
FDA批准摘要:用于治疗转移性去势抵抗性前列腺癌的镥-177维匹伐肽四环素
期刊:Clinical Cancer Research
影响因子:10.2
doi:10.1158/1078-0432.CCR-22-2875
Fallah, Jaleh; Agrawal, Sundeep; Gittleman, Haley; Fiero, Mallorie H; Subramaniam, Sriram; John, Christy; Chen, Wei; Ricks, Tiffany K; Niu, Gang; Fotenos, Anthony; Wang, Min; Chiang, Kelly; Pierce, William F; Suzman, Daniel L; Tang, Shenghui; Pazdur, Richard; Amiri-Kordestani, Laleh; Ibrahim, Amna; Kluetz, Paul G